

DOCKET NO.: P0633.70014US01

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonid A. Kozhemyakin, et al.  
Serial No.: 10/747,855  
Confirmation No.: 2748  
Filed: December 29, 2003  
For: METHODS AND PRODUCTION OF THE OXIDIZED  
GLUTATHIONE COMPOSITE WITH CIS-  
DIAMMINEDICHLOROPLATINUM AND  
PHARMACEUTICAL COMPOSITIONS BASED  
THEREOF REGULATING METABOLISM,  
PROLIFERATION, DIFFERENTIATION AND  
APOPTOTIC MECHANISMS FOR NORMAL AND  
TRANSFORMED CELLS

Examiner: Jeffrey E. Russel  
Art Unit: 1654

---

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 17 day of August, 2005.

  
Signature

---

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF  
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

PART II: Information Cited

The Applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Serial No.: 10/747,855  
Conf. No.: 2748


- 3 -

Art Unit: 1654

An early and favorable action is hereby requested.

Respectfully submitted,

By:


  
\_\_\_\_\_  
Timothy J. Oyer, Ph.D., Reg. No. 36,628  
Tani Chen, Sc.D., Reg. No. 52,728  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: P0633.70014US01

Date: August 17, 2005

x08/18/05x

927685



FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
				FILING DATE: Dec. 29, 2003	CONFIRMATION NO.: 2748
				APPLICANT: Leonid A. Kozhemyakin, et al.	
Sheet	1	of	1	GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

#### U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM/DD/YYYY
		Number	Kind Code		
	*A1	4,871,528		Tognella, et al.	10/03/1989
	*A2	5,104,852		Kralick, et al.	04/14/1992
	*A3	5,352,771		Kostic, et al.	10/04/1994
	*A4	5,789,000		Hausheer, et al.	08/04/1998
	*A5	6,159,500		Demopoulos, et al.	12/12/2000
	A6	6,312,734	B1	Kozhemyakin, et al.	11/06/2001

#### FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM/DD/YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	*B1	EP	0 265 719	A1		05/1988	
	*B2	WO	97/21443			06/19/1997	
	*B3	WO	97/21444			06/19/1997	

#### OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C1	C.D. Gregory, "Apoptosis: a role in neoplasia?", Cell Proliferation in Cancer Regulatory Mechanisms of Neoplastic Cell Growth, L. Pusztai & C.E. Lewis editors, Oxford University Press, Chapter 13, pp. 342-359, 1996	
	*C2	Lempers, et al., Reactions of [P+CL (dien)] CL with Glutathione..., Inorg. Chim. Acta. vol. 152, pp. 201-207, 1988	
	*C3	Ohta, et al., Reaction of oxidized glutathione..., Int. J. Pharmaceutics vol. 161, pp. 15-21, 1998	
	*C4	Raggi, et al. Spectrophotometric determination of thiols... , Pharmazie. vol. 53, No. 4, pp. 239-242, 1998	
	*C5	Raggi, et al., Studio della cinetica di reazione..., Boll. Chim. Farmaceutico. vol. 131, No. 8, pp. 318-319, 1992	
	*C6	A. Szent-Györgyi, "Charge Transfer and Electronic Mobility," Biochemistry, vol. 58, pp. 2012-2014, 1967	
	*C7	D.L. Vaux & A. Strasser, "The molecular biology of apoptosis," Proceedings of the National Academy of Sciences, Proc. Natl. Acad. Sci. USA, vol. 93, pp. 2239-2244, March 1996	

EXAMINER:

DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/241,232, filed February 1, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]